TYK2 Inhibition in Paradoxical Psoriasis - Trial NCT06281106
Access comprehensive clinical trial information for NCT06281106 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Prof Curdin Conrad and is currently Not yet recruiting. The study focuses on Psoriasis. Target enrollment is 26 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Prof Curdin Conrad
Centre Hospitalier Universitaire Vaudois
Timeline & Enrollment
Phase 2/3
Apr 01, 2024
Aug 01, 2025
Primary Outcome
Paradoxical Psoriasis Investigator Global Assessment
Summary
Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor
 agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or
 the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped
 and so far, no specific treatment for paradoxical psoriasis exists.
 
 This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a
 tablet taken by mouth once a day is superior compared to taking a placebo in treating
 paradoxical psoriasis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06281106
Non-Device Trial